Neurocrine Biosciences (NBIX) Financials

$139.49

$-2.76 (-1.94%)

As on 23-Sep-2026 16:22EDT

Market cap

$14,864 Mln

Revenue (TTM)

$3,374 Mln

P/E Ratio

22.2

P/B Ratio

4.2

Div. Yield

0 %

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Operating Revenue	3,373.90	2,860.50	2,355.30	1,887.10	1,488.70	1,133.50
Cost of Revenue	68.60	52.10	34.00	39.70	23.20	14.30
Gross Profit	3,305.30	2,808.40	2,321.30	1,847.40	1,465.50	1,119.20
Operating Expenses	2,516.40	2,189.30	1,750.80	1,596.50	1,216.50	1,016.70
Operating Profit (EBIT)	788.90	619.10	570.50	250.90	249.00	102.50
Other Income	--	--	--	--	-28.00	24.70
Profit before Tax	940.20	705.40	486.00	332.10	213.90	101.40
Provision for Tax	234.70	226.80	144.70	82.40	59.40	11.80
Profit after Tax (Net Income)	705.50	478.60	341.30	249.70	154.50	89.60
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	154.50	89.60

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Shareholder's Funds	3,693.60	3,253.10	2,589.70	2,232.00	1,707.80	1,374.00
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	791.00	635.00	621.30	364.60	123.20	452.70
Current Liabilities	874.50	743.40	507.70	654.80	537.70	245.80
Total Liabilities	6,233.60	4,631.50	3,718.70	3,251.40	2,368.70	2,072.50

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Non-Current Assets	3,721.60	2,108.80	1,994.00	1,644.40	915.20	1,099.70
Current Assets	1,637.50	2,522.70	1,724.70	1,607.00	1,453.50	972.80
Total Assets	6,233.60	4,631.50	3,718.70	3,251.40	2,368.70	2,072.50
Total Debt*	401.80	415.30	455.10	428.40	262.90	440.40
Net Current Assets	763.00	1,779.30	1,217.00	952.20	915.80	727.00

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Cash From Operating Activities	--	782.70	595.40	389.90	339.40	256.50
Cash Flow from Investing Activities	--	-264.40	-126.80	-467.10	-177.10	-130.20
Cash from Financing Activities	--	-38.30	-486.70	65.30	-234.30	27.40
Net Cash Inflow / Outflow	--	--	--	--	-72.00	153.70

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Adjusted EPS ($)	6.84	4.67	3.32	2.44	1.53	0.94
Cash EPS ($)	--	4.96	3.58	2.64	1.69	1.06
Adjusted Book Value ($)	--	31.74	25.17	21.82	16.94	14.48
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	7.64	5.79	3.81	3.37	2.70
Free Cash Flow per Share ($)	--	7.30	5.41	3.53	3.20	2.46

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
ROCE (%)	--	14.26	11.96	10.78	8.16	5.34
ROE (%)	20.31	16.38	14.16	12.68	10.03	7.17
ROA (%)	13.22	11.46	9.79	8.89	6.96	4.71
EBIT Margin (%)	25.81	22.25	26.01	20.92	16.73	11.22
Net Margin (%)	20.91	16.73	14.49	13.23	10.58	7.74
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Revenue Growth (%)	34.42	0.21	0.25	0.27	0.31	0.08
EBIT Growth (%)	60.49	3.90	55.17	58.55	95.75	-8.82
Net Profit Growth (%)	102.56	40.23	36.68	61.62	72.43	-78.00
EPS Growth (%)	101.99	0.41	0.36	0.59	0.62	-0.77
Book Value Growth (%)	32.88	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Price / Earnings	22.19	30.38	41.15	53.98	77.93	90.21
Price / Book Value	4.18	4.47	5.42	6.04	7.05	5.88
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	16.76	20.21	20.99	30.94	42.76	56.57
Close Price ($)	168.54	141.83	136.50	131.76	119.44	85.17
High Price ($)	171.50	160.18	157.98	133.64	129.29	120.27
Low Price ($)	122.14	84.23	110.95	89.04	71.88	78.31
Market Cap ($ Cr)	14,864.16	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Debt to Equity	--	0.13	0.18	0.19	0.15	0.32
Short term debt to equity ratio	--	--	--	0.08	0.10	0.01
Current Ratio	1.87	3.39	3.40	2.45	2.70	3.96
Quick Ratio	1.75	3.30	3.28	2.40	2.64	3.83
Interest Coverage	325.21	--	4.84	85.83	35.07	4.93

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Debtors to sales (%)	26.29	24.01	20.34	23.28	23.51	16.37
Asset Turnover	0.63	0.69	0.68	0.67	0.67	0.60
Receivable days	--	74.44	71.21	76.38	65.69	55.20
Inventory Days	--	443.07	514.04	337.65	516.39	747.10
Payable days	--	717.88	1,252.59	922.79	935.17	1,160.88
Cash Conversion Cycle	--	-200.38	-667.35	-508.75	-353.09	-358.58

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Income Statement ($ Mln)